Gout Relief 3310-S MEDICAGO SATIVA WHOLE CHICORY ROOT 104 mg/1.3g; 260 mg/1.3g; 91 mg/1.3g; 65 mg/1.3g; 169 mg/1.3g; 299 mg/1.3g; 26 mg/1.3g; 130 mg/1.3g; 2.6 mg/1.3g Capsule, 60-count
by Bispit Canada Ltd. · 60 CAPSULE in 1 BOTTLE (85631-006-01) / 1.3 g in 1 CAPSULE
NDC 85631-0006-01
🏷️ FDA NDC (as labeled)
85631-006-01
billing pads the product segment with a zero
OTC
On market
Non-controlled
🗂️ Data synced Sep 17, 2026 · sources: openFDA · FDA label (DailyMed) · FDA Orange & Purple Book · First Databank · CMS NADAC, ASP, Medicare & Medicaid · RxNorm
📋 All sources & update times →
🆔 Identity & classification
FDA NDC (as labeled)
85631-006-01
Product NDC
85631-006
11-digit billing NDC
85631000601
UNII
4Q4V6NTZ1F, DJO934BRBD, N0Y68724R3, GH42T47V24, M8YIA49Q2P, 090CTY533N +3 more
UPC
0850066597200
SPL Set ID
3dbf3436-16b9-b793-e063-6394a90a1e71
Established class (EPC)
Non-Standardized Food Allergenic Extract; Non-Standardized Plant Allergenic Extract
Physiologic effect
Increased Histamine Release; Cell-mediated Immunity
Chemical class
Allergens; Dietary Proteins; Plant Proteins
DEA schedule
Non-controlled
Marketing category
UNAPPROVED HOMEOPATHIC
Marketing status
On market
FDA listing status
Listed (active directory)
Marketing start
2025-09-01
Route
ORAL
Dosage form
CAPSULE
Substance
COIX LACRYMA-JOBI SEED; MEDICAGO SATIVA WHOLE; BUCKWHEAT; TEA LEAF; MORUS ALBA LEAF; CHICORY ROOT; FU LING; GLUCOSAMINE HYDROCHLORIDE; LICORICE
Why two NDCs?
The FDA registers this code as 85631-006-01 — a 5-3-2 layout, and that's what's printed on the package and shown on DailyMed. For insurance claims, every NDC is standardized to a uniform 11-digit 5-4-2 format by adding a zero to the product segment → 85631-0006-01. Same drug, same package — only the format differs.
Where does this data come from?
Identifiers from the FDA openFDA NDC Directory and Structured Product Labeling; RxCUI from RxNorm (NLM); GPI from Medi-Span; GCN / HIC / AHFS / legend from First Databank.
🏭 Manufacturer & labeler
LabelerBispit Canada Ltd.
Labeler code85631
First marketedSep 2025
Product typeHuman Otc Drug
Portfolio12 products on file
The labeler markets the product; the application holder owns the FDA approval. They’re often the same company but can differ (e.g. a repackager or an authorized generic). A mailing address / phone appears here when the manufacturer includes it in the product’s FDA label (not all do).
Where does this data come from?
Labeler, application holder and registered establishment from the FDA openFDA NDC Directory and Drugs@FDA; address/contact from the product’s FDA label.
🩺 Clinical
🧪 What is this product?
Gout Relief 3310-S is an unapproved homeopathic product sold as an oral capsule containing a blend of plant-based ingredients including buckwheat, chicory root, coix seed, fu ling, licorice, medicago sativa, morus alba leaf, tea leaf, and glucosamine hydrochloride. In homeopathic practice, these ingredients are traditionally used to support joint comfort and address symptoms associated with gout. Homeopathic products are marketed based on homeopathic tradition rather than FDA evaluation for effectiveness, and they are not evaluated by the FDA for safety or efficacy in the way conventional drugs are.
Patient education
Supplement & herbal interactions
Where does this data come from?
Plain-language summary from MedlinePlus (U.S. National Library of Medicine); supplement & herbal interactions and nutrient depletion data from the Natural Medicines database; our full guide is HelloPharmacist editorial content.
💬 Questions about MEDICAGO SATIVA WHOLE CHICORY ROOT?
Ask a pharmacist →
Ask a licensed pharmacist directly — free, answered by our team.
💊 What it looks like
Color
white
ShapeCapsule
Size2 mm
One label can cover several strengths, so colors may be combined — always confirm a loose pill against the dispensed prescription label or a pharmacist.
Where does this data come from?
Physical description (imprint, shape, color, scoring, coating) from this product’s FDA Structured Product Labeling (SPL), mirrored from DailyMed / openFDA.
🧪 Inactive Ingredients / Excipients
Inactive ingredients, also called excipients, are components of the drug product other than the active ingredient. They may include fillers, dyes, coatings, preservatives, flavors, or other formulation ingredients.
Loading inactive ingredients from the official FDA label in the background. No external source is being called by this page request.
Where does this data come from?
Source: official FDA Structured Product Labeling (SPL) via DailyMed and the openFDA label index. Structured
IACT rows and label-wide narrative are kept separate; availability and product-level specificity depend on the submitted label.Inactive ingredient FAQ
Are inactive ingredients the same for every manufacturer?
No. Inactive ingredients can differ by manufacturer, dosage form, strength, and package / product version.
Why might an inactive ingredient be missing?
Some SPLs do not provide a complete structured inactive-ingredient list, and older or unusual labels may only include the information in narrative text.
Can inactive ingredients matter?
Yes. They can matter for allergies, intolerances, dyes, gluten / lactose concerns, preservatives, and formulation differences — but confirm with a pharmacist or the manufacturer when it’s clinically important.
💲 Pricing
A drug doesn't have one price. Each row is a different public payment system, and none is what you'd pay at the counter — that depends on your insurance. The ⓘ on each row explains what it measures.
| Price system | Per each | Per package |
|---|---|---|
| Retail pharmacies payNADAC · weekly | Not in the retail survey — common for institutional, discontinued, or low-volume packs. | |
| Medicaid paysCMS SDUD · 12 mo | No recent Medicaid claims on file for this NDC — rare and low-volume NDCs are suppressed in the public data. | |
| Medicare drug plans payPart D · quarterly | No Part D plan price is available for this NDC in our data. | |
ℹ️
No price is published for this exact package yet. CMS surveys NADAC per package size, so a different pack of the same drug often has one.
Where does this data come from?
NADAC (National Average Drug Acquisition Cost) is the CMS weekly pharmacy-acquisition-cost survey — what pharmacies pay. ASP (Average Sales Price) is the CMS Medicare Part B drug-payment file, published quarterly. Medicaid pays is computed by us from CMS State Drug Utilization Data (total reimbursed ÷ units, trailing 12 months) — gross of rebates and inclusive of dispensing fees, so it reflects what Medicaid paid, not an acquisition cost. Medicare drug plans pay is the median negotiated point-of-sale unit cost across plans listing this NDC in the CMS quarterly Prescription Drug Plan pricing files, before rebates. The VA pays is the federal contract price (FSS, and the statutory Big 4 ceiling where listed) from the VA National Acquisition Center pharmaceutical price file. All are free public government data; each measures a different payer, so the figures are not directly comparable.
🔁 Therapeutic equivalents
| Product | Labeler | Pack | NADAC/unit | TE | Status | Price vs. this |
|---|---|---|---|---|---|---|
| Gout Relief 3310-S 104 mg/1.3g; 260 mg/1.3g; 91 mg/1.3g; 65 mg/1.3g; 169 mg/1.3g; 299 mg/1.3g; 26 mg/1.3g; 130 mg/1.3g; 2.6 mg/1.3gthis 85631-0006-01 | Bispit | 60 capsules | — | — | FDA listed | — |
About this product: other versions of the same ingredient, strength and form are listed above, least expensive first, with FDA equivalence ratings where available.
Where does this data come from?
Equivalents are other NDCs of the same ingredient, form and route from the openFDA NDC Directory, ranked least-expensive-first by NADAC. Therapeutic-equivalence (AB) ratings come from the FDA Orange Book; biologics use the FDA Purple Book for biosimilar & interchangeable status.
⏳ Availability & generic status
🏛️
2025
On the market since
Sep 2025
📍
2026
Currently FDA-listed
1 year listed
🔒
·
No generic listed yet
brand only
ℹ️No FDA-approved generic found
We did not find an FDA-approved generic match for this exact strength, form and route.
Where does this data come from?
Patents and exclusivity from the FDA Orange Book (small-molecule drugs), refreshed from public FDA data. Generic launch timing is an estimate, not a guarantee.
📦 Packaging — all sizes for this product
| Package NDC | Description | Marketing start | Status |
|---|---|---|---|
| 85631-0006-01 You're viewing this | 60 CAPSULE in 1 BOTTLE (85631-006-01) / 1.3 g in 1 CAPSULE | 2025-09-01 | Active |
🧭 About this NDC listing & data coverage
Over-the-counter (OTC) product
Homeopathic listing
About homeopathic listings
Gout Relief 3310-S MEDICAGO SATIVA WHOLE CHICORY ROOT 104 mg/1.3g; 260 mg/1.3g; 91 mg/1.3g; 65 mg/1.3g; 169 mg/1.3g; 299 mg/1.3g; 26 mg/1.3g; 130 mg/1.3g; 2.6 mg/1.3g CAPSULE is listed under the homeopathic marketing category. An NDC listing in this category does not by itself establish FDA approval, and FDA does not evaluate homeopathic products for effectiveness. This page reports the listing data as published.
What data is (and isn’t) available for this NDC — tap to expand
| NDC identity (package / product / labeler codes) | ✓ Available |
| Labeler | ✓ Available |
| Product & package description | ✓ Available |
| Marketing category & status | ✓ Available |
| Active ingredient / dosage form / route | ✓ Available |
| FDA label (SPL via DailyMed) | ✓ Available |
| Package photos | ✓ Available |
| Inactive ingredients (structured) | — Not published for this NDC The labeler did not submit a structured excipient list, or no SPL is available. |
| NADAC pharmacy acquisition price (CMS) | — Not published for this NDC CMS publishes NADAC only for NDCs reported in its retail-pharmacy survey. |
| Orange Book / therapeutic-equivalence data | — Not published for this NDC Applies only to products approved under an NDA/ANDA; many listings are out of scope. |
| HCPCS J-code billing crosswalk | — Not published for this NDC Most self-administered / retail products have no J-code — that is normal. |
| Medicaid utilization (CMS SDUD) | — Not published for this NDC CMS reports utilization only for NDCs with Medicaid claims above its privacy threshold. |
“Not published” reflects what the public FDA / CMS / NLM sources provide for this exact package code — it is a property of the data feeds, not a judgment about the product.
Questions about this listing
Is this NDC FDA-approved?
An NDC listing does not by itself establish FDA approval — the NDC Directory records that a product is listed with FDA, not that it was reviewed and approved. This listing's marketing category is "Unapproved Homeopathic". Products approved under an application carry an NDA, ANDA, or BLA number.
Why is there no price listed?
The pricing shown on our NDC pages comes from CMS NADAC, a voluntary survey of retail community pharmacy invoices. CMS does not publish a NADAC for every NDC — packages outside the retail survey (institutional and hospital products, bulk packages, discontinued items, and many OTC items) may never receive one. A missing price reflects the survey's scope, not this product's actual cost, and does not mean the product is free or unavailable.
Is the NDC printed on the package the same as the 11-digit billing NDC?
Yes, they identify this exact package in different formats. The FDA registers it as 85631-006-01, which is what is printed on the packaging and shown on DailyMed. Insurance claims use a fixed 11-digit 5-4-2 format, so the short segment is padded with a leading zero: 85631-0006-01, written without dashes as 85631000601. The Identity section at the top of this page lists every form of this code.
What do the three segments of this NDC mean?
In 85631-0006-01, the first segment (85631) is the labeler code FDA assigned to Bispit Canada Ltd.; the middle segment (0006) identifies this specific product — its ingredient, strength, and dosage form; and the last segment (01) identifies this exact package size and type. Together they name one specific package of one specific product.
Is this package still being marketed?
Yes, per the latest FDA NDC Directory data on this page: this package is listed as actively marketed, with no marketing end date reported by Bispit Canada Ltd.. Listing status can change — the directory data on this page refreshes weekly.
Who lists this product with the FDA?
Bispit Canada Ltd. is the labeler of record for this NDC — the company under whose FDA-assigned code the package is listed. The labeler may be the manufacturer itself or a distributor marketing the product under its own code.
Do I need a prescription for this product?
This NDC is listed with FDA as an over-the-counter product, so it does not require a prescription. Follow the package directions, and ask your pharmacist if you are unsure whether it is right for you.
This page identifies an FDA-listed package (the NDC) and reports public regulatory and pricing data about the listing. It is reference information, not a medical recommendation — talk to your pharmacist or prescriber about your own medication.
Where does this data come from?
Listing facts (marketing category, packager status, marketing dates) from the FDA openFDA NDC Directory; label availability from DailyMed; pricing coverage from CMS NADAC; equivalence scope from the FDA Orange Book.
📄 FDA label — Drug Facts FDA SPL
The complete FDA label for this product — the official Drug Facts labeling, verbatim, section by section. Jump with a chip, search within the label, or expand everything.
🎯 Indications and Usage
⏱️ Dosage and Administration
⚠️ Warnings
🧪 Active Ingredient
🧪 Inactive Ingredients
🎯 Purpose
🎯 Indications and Usage ▾
Dissolved CrystallizationKidney StoneGallstone< Urinary Calculus
⏱️ Dosage and Administration ▾
The product has great somatosensation after taking it atleast 21 days in the earty stage;3. Elevated uric acid or gout recurrence and site changes arenoral in the earty stage of taking this product;
⚠️ Warnings ▾
For your health, please read the followingcarefully 1. The use of three vials can effectivety dissolve crystallization (ittakes time to dissolve crystallization);2. The product has great somatosensation after taking it atleast 21 days in the early stage;3.
Elevated uric acid or gout recurrence and site changes arenormal in the early stage of taking this product;4. Try not to drink alcohol or drink less 15 days before takingthis product; 5. This product certainly has significant effect on gout,crystallization and hyperuricemia;
🧪 Active Ingredient ▾
MEDICAGO SATIVA WHOLE 20.00% CHICORY ROOT 23.00% GLUCOSAMINE HYDROCHLORIDE 10.00% BUCKWHEAT 7.00% TEA LEAF 5.00% MORUS ALBA LEAF 13.00% LICORICE 0.20% FU LING 2.00% COIX LACRYMA-JOBI SEED 8.00%
🧪 Inactive Ingredients ▾
This product has a significanteffect on gout, crystal deposits,and hyperuricemia; elt has an auxiliary effectof mitigating kidney stonesand bladder stones
🎯 Purpose ▾
This product has a significanteffect on gout, crystal deposits,and hyperuricemia; elt has an auxiliary effectof mitigating kidney stonesand bladder stones
No label section mentions that — try another word, or open the full label on DailyMed below.
Source: FDA Structured Product Labeling, mirrored from DailyMed / openFDA.
Prefer the government’s original formatting? View this label on DailyMed ↗
For educational and professional reference only — not medical advice. Pricing reflects published
NADAC and CMS ASP (free public data) and may differ from your acquisition cost; always verify before billing or dispensing.